Registry reportScientific Registry of the International Society for Heart and Lung Transplantation: Introduction to the 2005 Annual Reports
Section snippets
New data analysis types
In addition to our usual analyses, there are several new features in this year’s Registry reports. First, we have expanded the analyses of the use of newer immunosuppressive drugs and drug combinations. In addition, we have included analyses of the influence of induction and maintenance immunosuppressive drugs and combinations on the incidence of acute rejection and survival after transplantation. Finally, we have constructed hypothetical clinical scenarios that graphically illustrate the
Simplified reporting of “Tier 1” data
As promised in the Introduction to last year’s Registry reports, we have now implemented a simplified, online “Tier 1” data entry process, which requires only 14 data elements to register a patient, and only 3 data elements to complete the annual update for a patient. A new transplant case can be registered in as little as 2 minutes! By providing this less labor-intensive pathway for data reporting, we hope to improve the Registry’s ability to reflect the total number of transplants performed
Access to Registry data
There are many ways to access the Registry data (Table 1). As in past years, all data figures and tables included in the Registry reports are also available for viewing and downloading on the ISHLT website (www.ishlt.org/registries) in Microsoft PowerPoint format. The website also contains many additional data slides that are not included in the published reports. In addition, those wishing to view the published Heart, Lung and Heart-Lung, Pediatric and MCSD reports online may do so by
Requests for additional data and data analyses
ISHLT members and non-members frequently request Registry data that are not readily available in the slide set or in the continent- or center-specific reports. To facilitate and expedite these data queries, we have developed a uniform process by which they are handled. All requests are first submitted to the ISHLT headquarters office, accompanied by a data request form (available at www.ishlt.org). ISHLT staff will determine the number of hours each request will require, allowing each request
References (0)
Cited by (9)
Lung transplantation for cystic fibrosis: Current concepts and one center's experience
2007, Journal of Cystic FibrosisCitation Excerpt :The choices available for induction therapy with polyclonal or monoclonal antibodies are antithymocyte globulin (ATG), muromonab-CD3 (OKT3) or IL-2 receptor antagonists (basiliximab or daclizumab). The most recent report from the ISHLT shows that slightly less than 45% of adult lung recipients have had induction immunosuppression with one of these antibodies [3]. The IL-2 receptor antagonists are the most commonly used.
Spanish heart transplant units consensus conference
2007, Revista Espanola de Cardiologia SuplementosIdentification of a cardiac allograft rejection marker using microarray gene expression analysis in lymphocytes from heart transplant patients [4]
2007, Revista Espanola de CardiologiaCyclic AMP prolongs graft survival by suppressing apoptosis and inflammatory gene expression in acute cardiac allograft rejection
2010, Experimental and Molecular MedicineEisenmenger syndrome: An overview
2008, Tijdschrift voor Geneeskunde